Compare Cisco Systems Inc (CSCO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cisco Systems Inc vs TG Therapeutics Inc — how do they compare? Cisco Systems Inc trades at $118.39 (market cap $452.96B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Cisco Systems Inc is far larger — about 55.5× TG Therapeutics Inc's market cap, and Cisco Systems Inc pays a 1.46% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cisco Systems Inc for 86 Days and TG Therapeutics Inc for 16 Days on average.
| CSCO | TGTX | |
|---|---|---|
Market Cap | $452.96B | $8.16B |
Volume | 12,951,578 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $130.00 | $59.06 |
52-Week Low | $67.46 | $26.94 |
Typical Hold Time | 86 Days | 16 Days |
Enterprise Value | $466.58B | $8.37B |
Dividend Yield | 1.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cisco Systems (CSCO) trades at $114.89, down 2.13% on the day, amid a bullish technical outlook supported by moving averages and strong institutional sentiment. The company reported robust Q2 2026 EPS of $1.22, beating estimates, with revenue growth driven by AI networking demand. Analysts maintain a 51.35% buy rating with a $129.77 consensus target, highlighting multi-year growth potential from AI infrastructure and Splunk integration.
The stock presents a favorable risk-reward profile with solid fundamentals, including a 20.95% net margin and consistent earnings beats. Key risks include competitive pressures in AI security and cyclical IT spending. Upside is supported by strong cash flow and strategic partnerships, though valuation multiples like a 34.5 P/E warrant monitoring amid macroeconomic uncertainties.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
